Blend Cagrilintide + Semaglutide
$109.00
CagriSema is an investigational dual-mechanism compound combining Cagrilintide, a long-acting amylin analog, with Semaglutide, a GLP-1 receptor agonist. Studied in Phase III clinical trials for complementary gut-brain axis modulation, glycemic regulation, and cardiometabolic pathway research under the REDEFINE program.
What Is Cagrilintide + Semaglutide (CagriSema)?
CagriSema is an investigational fixed-dose combination of two distinct molecular agents: Cagrilintide — a long-acting synthetic amylin analog targeting AMYR1–3 receptors — and Semaglutide — a GLP-1 receptor agonist with established pharmacological characterization. The combination engages two separate but complementary neuroendocrine axes involved in appetite regulation, postprandial glucose management, and metabolic signaling, currently under active Phase III clinical investigation sponsored by Novo Nordisk A/S.
Mechanism of Action
Semaglutide binds selectively to GLP-1 receptors located in the pancreas, hypothalamus, and brainstem, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Cagrilintide acts via amylin receptors (AMYR1–3) in the brainstem and hypothalamus to enhance satiety signaling and further delay gastric emptying through pathways distinct from GLP-1 receptor activation. The dual receptor engagement produces additive effects on the gut-brain axis, with each agent operating through independent but mechanistically complementary downstream cascades.
Research & Clinical Trial Data
CagriSema is currently under evaluation across multiple registered Phase III trials:
- REDEFINE 1 (NCT05567796) — Phase IIIa; mean body weight reduction outcomes published in The New England Journal of Medicine
- NCT07011667 — Long-term weight maintenance; Active, not recruiting
- NCT06131372 — Chronic kidney disease + T2D cohort; Phase II, Completed
- NCT07253285 — Pediatric population; Phase III, Recruiting
Purity & Quality
Reference-grade material. Certificate of Analysis available per batch. Regulatory status: not approved by FDA or EMA for general therapeutic use as of current listing date.
Cagrilintide Class: Long-acting amylin analog | Semaglutide Class: GLP-1 receptor agonist | Administration: Subcutaneous | Sponsor: Novo Nordisk A/S | Storage: 2–8°C refrigerated, protect from light
| Select mg | 5mg + 5mg |
|---|
Related products
-
All
Melanotan 2
$59.00 Select options This product has multiple variants. The options may be chosen on the product page -
All
KLOW
$149.00 Select options This product has multiple variants. The options may be chosen on the product page -
All
Cagrilintide
$99.00 Select options This product has multiple variants. The options may be chosen on the product page -
All
NAD+
$89.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.